Evidence map›Paper›PMID 29071280›Full record

ArticleMolecular biology research communications2017

Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study.

Partha Sarathi Mohanty, Farah Naaz, Avi Kumar Bansal, Umesh Datta Gupta

Open access · greenAbstract read
In one paragraph

Article in Molecular biology research communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Partha Sarathi MohantyMicrobiology and Molecular Biology National JALMA Institute for Leprosy and Other Mycobacterial Diseases Agra, India.
Farah NaazMicrobiology and Molecular Biology National JALMA Institute for Leprosy and Other Mycobacterial Diseases Agra, India.
Avi Kumar BansalMedical Division National JALMA Institute for Leprosy and Other Mycobacterial Diseases Agra, India.
Umesh Datta GuptaNational JALMA Institute for Leprosy and Other Mycobacterial Diseases Agra, India.
National JALMA Institute for Leprosy & Other Mycobacterial Diseases · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of drug resistance in leprosy is a major hurdle in leprosy elimination programme. Although the problem of drug resistance is presently not acute, it is important that we collect data more systematically and monitor the trend carefully so that effective measures to combat this problem can be developed. The present study aimed at the explication of cross resistance of rifabutin and rifapentine to rifampicin which would be helpful to programme managers for implementing rifabutin or rifapentine in replace of rifampicin. In this study we built 3D model of the

Indexed as

DockingDrug resistanceLeprosyRifabutinRifampicinRifapentine

Identifiers

PMID29071280
PMCPMC5640893
OpenAlexW2705354885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.